Sacituzumab govitecan治疗经治HR+/HER2-转移性乳腺癌:I/II期单臂篮式试验最终结果
该研究分析了I/II期单臂篮式试验中54例经内分泌治疗和至少一线化疗后进展的HR+/HER2-转移性乳腺癌患者,接受静脉Sacituzumab govitecan(10 mg/kg)治疗。中位随访11.5个月,客观缓解率为31.5%(95%CI 19.5%-45.6%),中位无进展生存期5.5个月,中位总生存期12个月,常见≥3级治疗相关不良事件为中性粒细胞减少(50.0%)、贫血(11.1%)和腹泻(7.4%)。
要点
- SG在经治HR+/HER2-转移性乳腺癌中ORR达31.5%,中位PFS 5.5个月。
- 常见≥3级毒性为中性粒细胞减少(50.0%)、贫血(11.1%)和腹泻(7.4%)。
- 未发生治疗相关死亡,仅2例因不良事件停药。
核心结论
- Sacituzumab govitecan在经治HR+/HER2-转移性乳腺癌中显示出令人鼓舞的抗肿瘤活性和可预测、可管理的安全性特征。
研究设计与样本
- I/II期单臂篮式试验(NCT01631552)的预设亚组分析,纳入54例经内分泌治疗和至少一线化疗后进展的HR+/HER2-转移性乳腺癌女性患者。
主要发现
- 中位随访11.5个月,客观缓解率为31.5%(95%CI 19.5%-45.6%),其中17例部分缓解。
- 中位缓解持续时间为8.7个月(95%CI 3.7-12.7),中位无进展生存期为5.5个月(95%CI 3.6-7.6),中位总生存期为12个月(95%CI 9.0-18.2)。
- ≥3级治疗相关毒性包括中性粒细胞减少(50.0%)、贫血(11.1%)和腹泻(7.4%);2例因治疗相关不良事件停药,无治疗相关死亡。
临床怎么用
- 对于经内分泌治疗和至少一线化疗后进展的HR+/HER2-转移性乳腺癌患者,SG可作为候选治疗选择,但需密切监测中性粒细胞减少、贫血和腹泻。
局限性
- 本研究为单臂I/II期试验的亚组分析,样本量有限(54例),缺乏随机对照,结论需III期随机试验(TROPiCS-02)进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Trophoblast cell-surface antigen-2 (Trop-2) is expressed in epithelial cancers, including hormone receptor-positive (HR+) metastatic breast cancer (mBC). Sacituzumab govitecan (SG; Trodelvy®) is an antibody-drug conjugate composed of a humanized anti-Trop-2 monoclonal antibody coupled to SN-38 at a high drug-to-antibody ratio via a unique hydrolyzable linker that delivers SN-38 intracellularly and in the tumor microenvironment. SG was granted accelerated FDA approval for metastatic triple-negative BC treatment in April 2020. PATIENTS AND METHODS: We analyzed a prespecified subpopulation of patients with HR+/human epidermal growth factor receptor 2-negative (HER2-) HR+/HER2- mBC from the phase I/II, single-arm trial (NCT01631552), who received intravenous SG (10 mg/kg) and whose disease progressed on endocrine-based therapy and at least one prior chemotherapy for mBC. End points included objective response rate (ORR; RECIST version 1.1) assessed locally, duration of response (DOR), clinical benefit rate, progression-free survival (PFS), overall survival (OS), and safety. RESULTS: Fifty-four women were enrolled between 13 February 2015 and 1 June 2017. Median (range) age was 54 (33-79) years and all received at least two prior lines of therapy for mBC. At data cut-off (1 March 2019), 12 patients were still alive. Key grade ≥3 treatment-related toxicities included neutropenia (50.0%), anemia (11.1%), and diarrhea (7.4%). Two patients discontinued treatment due to treatment-related adverse events. No treatment-related deaths occurred. At a median follow-up of 11.5 months, the ORR was 31.5% [95% confidence interval (CI), 19.5%-45.6%; 17 partial responses]; median DOR was 8.7 months (95% CI 3.7-12.7), median PFS was 5.5 months (95% CI 3.6-7.6), and median OS was 12 months (95% CI 9.0-18.2). CONCLUSIONS: SG shows encouraging activity in patients with pretreated HR+/HER2- mBC and a predictable, manageable safety profile. Further evaluation in a randomized phase III trial (TROPiCS-02) is ongoing (NCT03901339). TRIAL REGISTRATION: ClinicalTrials.gov NCT01631552; https://clinicaltrials.gov/ct2/show/NCT01631552.
引用
- Kalinsky K, Diamond JR, Vahdat LT, et al. Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial. Ann Oncol. 2020. PMID: 32946924. doi:10.1016/j.annonc.2020.09.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。